This rare condition affects only 2-10 out of every 100,000 people and is the second leading cause of blindness from optic nerve damage, following glaucoma
NEW YORK, August 1, 2026 (Newswire.com) - Quick disclosure before you dive in: this is a paid advertorial, and a commission may be earned if you enroll through a link here
We combine advanced medical science with modern technology to deliver results-oriented, personalized solutions
How can I start using oral tirzepatide
No previous pharmaceutical treatment has shown such consistent cross-gender efficacy at this magnitude
However, the combination isnt without risks, particularly for individuals who are prone to low blood sugar